The better understanding of the biological behavior of multiple endocrine neoplasia type 1 (MEN1) organ manifestations and the increase in clinical experience warrant a revision of previously published guidelines. Duodenopancreatic neuroendocrine neoplasias (DP-NENs) are still the second most common manifestation in MEN1 and, besides NENs of the thymus, remain a leading cause of death. DP-NENs are thus of main interest in the effort to reevaluate recommendations for their diagnosis and treatment. Especially over the last 2 years, more clinical experience has documented the follow-up of treated and untreated (natural-course) DP-NENs. It was the aim of the international consortium of experts in endocrinology, genetics, radiology, surgery, gastroenterology, and oncology to systematically review the literature and to present a consensus statement based on the highest levels of evidence. Reviewing the literature published over the past decade, the focus was on the diagnosis of F- and NF-DP-NENs within the MEN1 syndrome in an effort to further standardize and improve treatment and follow-up, as well as to establish a “logbook” for the diagnosis and treatment of DP-NENs. This shall help further reduce complications and improve long-term treatment results in these rare tumors. The following international consensus statement builds upon the previously published guidelines of 2001 and 2012 and attempts to supplement the recommendations issued by various national and international societies.

1.
Chandrasekharappa
SC
,
Guru
SC
,
Manickam
P
,
Olufemi
SE
,
Collins
FS
,
Emmert-Buck
MR
, et al.
Positional cloning of the gene for multiple endocrine neoplasia-type 1
.
Science
.
1997
;
276
(
5311
):
404
7
.
2.
Lemmens
I
,
Van de Ven
WJ
,
Kas
K
,
Zhang
CX
,
Giraud
S
,
Wautot
V
, et al.
Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1
.
Hum Mol Genet
.
1997
;
6
(
7
):
1177
83
. .
3.
Thakker
RV
.
Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)
.
Mol Cell Endocrinol
.
2014
;
386
(
1–2
):
2
15
. .
4.
Brandi
ML
,
Gagel
RF
,
Angeli
A
,
Bilezikian
JP
,
Beck-Peccoz
P
,
Bordi
C
, et al.
Guidelines for diagnosis and therapy of MEN type 1 and type 2
.
J Clin Endocrinol Metab
.
2001
;
86
(
12
):
5658
71
. .
5.
Lemos
MC
,
Thakker
RV
.
Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene
.
Hum Mutat
.
2008
;
29
(
1
):
22
32
. .
6.
Turner
JJ
,
Christie
PT
,
Pearce
SH
,
Turnpenny
PD
,
Thakker
RV
.
Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type 1 (MEN1)
.
Hum Mutat
.
2010
;
31
(
1
):
E1089
101
. .
7.
Newey
PJ
,
Thakker
RV
.
Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice
.
Endocr Pract
.
2011
;
17
(
Suppl 3
):
8
17
. .
8.
Thakker
RV
,
Newey
PJ
,
Walls
GV
,
Bilezikian
J
,
Dralle
H
,
Ebeling
PR
, et al.
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)
.
J Clin Endocrinol Metab
.
2012
;
97
(
9
):
2990
3011
. .
9.
van Leeuwaarde
RS
,
Dreijerink
KM
,
Ausems
MG
,
Beijers
HJ
,
Dekkers
OM
,
de Herder
WW
, et al.
MEN1-dependent breast cancer: indication for early screening? Results from the Dutch MEN1 Study Group
.
J Clin Endocrinol Metab
.
2017
;
102
(
6
):
2083
90
. .
10.
Falconi
M
,
Eriksson
B
,
Kaltsas
G
,
Bartsch
DK
,
Capdevila
J
,
Caplin
M
, et al.
ENETS Consensus Guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors
.
Neuroendocrinology
.
2016
;
103
(
2
):
153
71
. .
11.
Yates
CJ
,
Newey
PJ
,
Thakker
RV
.
Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1
.
Lancet Diabetes Endocrinol
.
2015
;
3
(
11
):
895
905
. .
12.
Jensen
RT
,
Bodei
L
,
Capdevila
J
,
Couvelard
A
,
Falconi
M
,
Glasberg
S
, et al.
The EMABP, participants EMAB: unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms
.
Neuroendocrinology
.
2019
;
108
:
26
36
.
13.
Kunz
PL
,
Reidy-Lagunes
D
,
Anthony
LB
,
Bertino
EM
,
Brendtro
K
,
Chan
JA
, et al.
North American Neuroendocrine Tumor Society: consensus guidelines for the management and treatment of neuroendocrine tumors
.
Pancreas
.
2013
;
42
:
557
77
.
14.
NCCN: Neuroendocrine and Adrenal Tumors Version 4. 2018. Clinical Practice Guidelines in Oncology, 2019. Available from: www.nccn.org
.
15.
Marini
F
,
Giusti
F
,
Brandi
ML
.
Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients
.
Orphanet J Rare Dis
.
2018
;
13
(
1
):
205
. .
16.
Trump
D
,
Farren
B
,
Wooding
C
,
Pang
JT
,
Besser
GM
,
Buchanan
KD
, et al.
Clinical studies of multiple endocrine neoplasia type 1 (MEN1)
.
QJM
.
1996
;
89
:
653
69
.
17.
Manoharan
J
,
Albers
MB
,
Bartsch
DK
.
The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies
.
Endocr Relat Cancer
.
2017
;
24
(
10
):
T209
25
. .
18.
Machens
A
,
Schaaf
L
,
Karges
W
,
Frank-Raue
K
,
Bartsch
DK
,
Rothmund
M
, et al.
Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers
.
Clin Endocrinol
.
2007
;
67
(
4
):
613
22
. .
19.
Marx
SJ
,
Vinik
AI
,
Santen
RJ
,
Floyd
JC
 Jr.
,
Mills
JL
,
Green
J
 3rd
.
Multiple endocrine neoplasia type I: assessment of laboratory tests to screen for the gene in a large kindred
.
Medicine
.
1986
;
65
(
4
):
226
41
. .
20.
Bassett
JH
,
Forbes
SA
,
Pannett
AA
,
Lloyd
SE
,
Christie
PT
,
Wooding
C
, et al.
Characterization of mutations in patients with multiple endocrine neoplasia type 1
.
Am J Hum Genet
.
1998
;
62
(
2
):
232
44
. .
21.
Goncalves
TD
,
Toledo
RA
,
Sekiya
T
,
Matuguma
SE
,
Maluf Filho
F
,
Rocha
MS
, et al.
Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life
.
J Clin Endocrinol Metabol
.
2014
;
99
:
E89
96
.
22.
Manoharan
J
,
Raue
F
,
Lopez
CL
,
Albers
MB
,
Bollmann
C
,
Fendrich
V
, et al.
Is routine screening of young asymptomatic MEN1 patients necessary?
World J Surg
.
2017
;
41
(
8
):
2026
32
. .
23.
Kann
PH
,
Balakina
E
,
Ivan
D
,
Bartsch
DK
,
Meyer
S
,
Klose
KJ
, et al.
Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study
.
Endocr Relat Cancer
.
2006
;
13
(
4
):
1195
202
. .
24.
Waldmann
J
,
Fendrich
V
,
Habbe
N
,
Bartsch
DK
,
Slater
EP
,
Kann
PH
, et al.
Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value
.
World J Surg
.
2009
;
33
(
6
):
1208
18
. .
25.
Kappelle
WF
,
Valk
GD
,
Leenders
M
,
Moons
LM
,
Bogte
A
,
Siersema
PD
, et al.
Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study
.
Endoscopy
.
2017
;
49
(
1
):
27
34
. .
26.
Anlauf
M
,
Schlenger
R
,
Perren
A
,
Bauersfeld
J
,
Koch
CA
,
Dralle
H
, et al.
Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome
.
Am J Surg Pathol
.
2006
;
30
(
5
):
560
74
. .
27.
Triponez
F
,
Dosseh
D
,
Goudet
P
,
Cougard
P
,
Bauters
C
,
Murat
A
, et al.
Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas
.
Ann Surg
.
2006
;
243
(
2
):
265
72
. .
28.
Jensen
RT
,
Berna
MJ
,
Bingham
DB
,
Norton
JA
.
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies
.
Cancer
.
2008
;
113
(
7 Suppl
):
1807
43
. .
29.
Fraenkel
M
,
Kim
MK
,
Faggiano
A
,
Valk
GD
.
Epidemiology of gastroenteropancreatic neuroendocrine tumours
.
Best Pract Res Clin Gastroenterol
.
2012
;
26
(
6
):
691
703
. .
30.
Triponez
F
,
Goudet
P
,
Dosseh
D
,
Cougard
P
,
Bauters
C
,
Murat
A
, et al.
Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE
.
World J Surg
.
2006
;
30
:
654
62
;
discussion 663–54
.
31.
Ito
T
,
Igarashi
H
,
Uehara
H
,
Berna
MJ
,
Jensen
RT
.
Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors
.
Medicine
.
2013
;
92
(
3
):
135
81
. .
32.
Benson
L
,
Ljunghall
S
,
Akerström
G
,
Oberg
K
.
Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1
.
Am J Med
.
1987
;
82
(
4
):
731
7
. .
33.
Vasen
HF
,
Lamers
CB
,
Lips
CJ
.
Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands
.
Arch Intern Med
.
1989
;
149
(
12
):
2717
22
. .
34.
Skogseid
B
,
Larsson
C
,
Lindgren
PG
,
Kvanta
E
,
Rastad
J
,
Theodorsson
E
, et al.
Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1
.
J Clin Endocrinol Metab
.
1992
;
75
(
1
):
76
81
. .
35.
Burgess
JR
,
Greenaway
TM
,
Shepherd
JJ
.
Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1
.
J Intern Med
.
1998
;
243
(
6
):
465
70
. .
36.
Carty
SE
,
Helm
AK
,
Amico
JA
,
Clarke
MR
,
Foley
TP
,
Watson
CG
, et al.
The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1
.
Surgery
.
1998
;
124
(
6
):
1106
4
;
discussion 1113–04
. .
37.
Levy-Bohbot
N
,
Merle
C
,
Goudet
P
,
Delemer
B
,
Calender
A
,
Jolly
D
, et al.
Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry
.
Gastroenterol Clin Biol
.
2004
;
28
:
1075
81
.
38.
Pieterman
CR
,
Schreinemakers
JM
,
Koppeschaar
HP
,
Vriens
MR
,
Rinkes
IH
,
Zonnenberg
BA
, et al.
Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome
.
Clin Endocrinol
.
2009
;
70
(
4
):
575
81
. .
39.
Goudet
P
,
Bonithon-Kopp
C
,
Murat
A
,
Ruszniewski
P
,
Niccoli
P
,
Ménégaux
F
, et al.
Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d’etude des Tumeurs Endocrines
.
Eur J Endocrinol
.
2011
;
165
(
1
):
97
105
. .
40.
Pieterman
CR
,
Vriens
MR
,
Dreijerink
KM
,
van der Luijt
RB
,
Valk
GD
.
Care for patients with multiple endocrine neoplasia type 1: the current evidence base
.
Fam Cancer
.
2011
;
10
(
1
):
157
71
. .
41.
Giudici
F
,
Nesi
G
,
Brandi
ML
,
Tonelli
F
.
Surgical management of insulinomas in multiple endocrine neoplasia type 1
.
Pancreas
.
2012
;
41
(
4
):
547
53
. .
42.
Conemans
EB
,
Nell
S
,
Pieterman
CRC
,
de Herder
WW
,
Dekkers
OM
,
Hermus
AR
, et al.
Prognostic factors for survival of Men1 patients with duodenopancreatic tumors metastatic to the liver: results from the DMSG
.
Endocr Pract
.
2017
;
23
(
6
):
641
8
. .
43.
Giusti
F
,
Cianferotti
L
,
Boaretto
F
,
Cetani
F
,
Cioppi
F
,
Colao
A
.
Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database
.
Endocrine
.
2017
;
58
(
2
):
349
59
.
44.
Albers
MB
,
Manoharan
J
,
Bollmann
C
,
Chlosta
MP
,
Holzer
K
,
Bartsch
DK
.
Results of duodenopancreatic reoperations in multiple endocrine neoplasia type 1
.
World J Surg
.
2019
;
43
(
2
):
552
8
.
45.
Wamsteker
EJ
,
Gauger
PG
,
Thompson
NW
,
Scheiman
JM
.
EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia
.
Gastrointest Endosc
.
2003
;
58
(
4
):
531
5
. .
46.
Kouvaraki
MA
,
Shapiro
SE
,
Cote
GJ
,
Lee
JE
,
Yao
JC
,
Waguespack
SG
, et al.
Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1
.
World J Surg
.
2006
;
30
(
5
):
643
53
. .
47.
Thomas-Marques
L
,
Murat
A
,
Delemer
B
,
Penfornis
A
,
Cardot-Bauters
C
,
Baudin
E
, et al.
Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1
.
Am J Gastroenterol
.
2006
;
101
:
266
73
.
48.
Vierimaa
O
,
Ebeling
TM
,
Kytölä
S
,
Bloigu
R
,
Eloranta
E
,
Salmi
J
, et al.
Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation
.
Eur J Endocrinol
.
2007
;
157
(
3
):
285
94
.
49.
Lopez
CL
,
Waldmann
J
,
Fendrich
V
,
Langer
P
,
Kann
PH
,
Bartsch
DK
.
Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1
.
Langenbecks Arch Surg
.
2011
;
396
(
8
):
1187
96
. .
50.
Sakurai
A
,
Yamazaki
M
,
Suzuki
S
,
Fukushima
T
,
Imai
T
,
Kikumori
T
, et al.
Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1: analysis of the database of the MEN Consortium of Japan
.
Endocr J
.
2012
;
59
(
10
):
859
66
. .
51.
Goudet
P
,
Dalac
A
,
Le Bras
M
,
Cardot-Bauters
C
,
Niccoli
P
,
Levy-Bohbot
N
, et al.
MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’etude des Tumeurs Endocrines
.
J Clin Endocrinol Metab
.
2015
;
100
:
1568
77
.
52.
Manoharan
J
,
Bollmann
C
,
Kann
PH
,
Di Fazio
P
,
Bartsch
DK
,
Albers
MB
.
Gender differences in multiple endocrine neoplasia type 1: implications for screening?
Visc Med
.
2020
;
36
(
1
):
3
9
. .
53.
de Laat
JM
,
Pieterman
CR
,
Weijmans
M
,
Hermus
AR
,
Dekkers
OM
,
de Herder
WW
, et al.
Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients
.
J Clin Endocrinol Metab
.
2013
;
98
(
10
):
4143
51
. .
54.
Ito
T
,
Jensen
RT
.
Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies
.
Int J Endocr Oncol
.
2016
;
3
(
1
):
53
66
. .
55.
Jensen
RT
,
Cadiot
G
,
Brandi
ML
,
de Herder
WW
,
Kaltsas
G
,
Komminoth
P
, et al.
ENETS Consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes
.
Neuroendocrinology
.
2012
;
95
(
2
):
98
119
. .
56.
Qiu
W
,
Christakis
I
,
Silva
A
,
Bassett
RL
 Jr
,
Cao
L
,
Meng
QH
, et al.
Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients
.
Clin Endocrinol
.
2016
;
85
(
3
):
400
7
. .
57.
Goswami
S
,
Peipert
BJ
,
Helenowski
I
,
Yount
SE
,
Sturgeon
C
.
Disease and treatment factors associated with lower quality of life scores in adults with multiple endocrine neoplasia type I
.
Surgery
.
2017
;
162
(
6
):
1270
7
. .
58.
Stromsvik
N
,
Nordin
K
,
Berglund
G
,
Engebretsen
LF
,
Hansson
MG
,
Gjengedal
E
.
Living with multiple endocrine neoplasia type 1: decent care-insufficient medical and genetic information: a qualitative study of MEN 1 patients in a Swedish hospital
.
J Genet Couns
.
2007
;
16
:
105
17
.
59.
Ito
T
,
Cadiot
G
,
Jensen
RT
.
Diagnosis of Zollinger-Ellison syndrome: increasingly difficult
.
World J Gastroenterol
.
2012
;
18
(
39
):
5495
503
. .
60.
Ito
T
,
Igarashi
H
,
Jensen
RT
.
Zollinger-Ellison syndrome: recent advances and controversies
.
Curr Opin Gastroenterol
.
2013
;
29
(
6
):
650
61
. .
61.
Metz
DC
,
Cadiot
G
,
Poitras
P
,
Ito
T
,
Jensen
RT
.
Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing
.
Int J Endocr Oncol
.
2017
;
4
(
4
):
167
85
. .
62.
Oh
DS
,
Wang
HS
,
Ohning
GV
,
Pisegna
JR
.
Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome
.
Clin Gastroenterol Hepatol
.
2006
;
4
(
12
):
1467
73
. .
63.
Jensen
RT
,
Niederle
B
,
Mitry
E
,
Ramage
JK
,
Steinmuller
T
,
Lewington
V
;
European Neuroendocrine Tumor S
, et al.
Gastrinoma (duodenal and pancreatic)
.
Neuroendocrinology
.
2006
;
84
(
3
):
173
82
. .
64.
Poitras
P
,
Gingras
MH
,
Rehfeld
JF
.
The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment
.
Clin Gastroenterol Hepatol
.
2012
;
10
(
2
):
199
202
. .
65.
Poitras
P
,
Gingras
MH
,
Rehfeld
JF
.
Secretin stimulation test for gastrin release in Zollinger-Ellison syndrome: to do or not to do?
Pancreas
.
2013
;
42
(
6
):
903
4
. .
66.
Rehfeld
JF
,
Bardram
L
,
Hilsted
L
,
Goetze
JP
.
An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control
.
Biomark Med
.
2014
;
8
(
4
):
571
80
. .
67.
Rehfeld
JF
,
Bardram
L
,
Hilsted
L
,
Poitras
P
,
Goetze
JP
.
Pitfalls in diagnostic gastrin measurements
.
Clin Chem
.
2012
;
58
(
5
):
831
6
. .
68.
Rehfeld
JF
,
Gingras
MH
,
Bardram
L
,
Hilsted
L
,
Goetze
JP
,
Poitras
P
.
The Zollinger-Ellison syndrome and mismeasurement of gastrin
.
Gastroenterology
.
2011
;
140
(
5
):
1444
53
. .
69.
Shah
P
,
Guo
T
,
Moore
DD
,
Ghose
R
.
Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters
.
Drug Metab Dispos
.
2014
;
42
(
1
):
172
81
. .
70.
Shibata
C
,
Kakyo
M
,
Kinouchi
M
,
Tanaka
N
,
Miura
K
,
Naitoh
T
, et al.
Criteria for the glucagon provocative test in the diagnosis of gastrinoma
.
Surg Today
.
2013
;
43
(
11
):
1281
5
. .
71.
Ito
T
,
Igarashi
H
,
Jensen
RT
.
Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances
.
Best Pract Res Clin Gastroenterol
.
2012
;
26
(
6
):
737
53
. .
72.
Norton
JA
,
Krampitz
G
,
Jensen
RT
.
Multiple endocrine neoplasia: genetics and clinical management
.
Surg Oncol Clin N Am
.
2015
;
24
(
4
):
795
832
. .
73.
Berna
MJ
,
Annibale
B
,
Marignani
M
,
Luong
TV
,
Corleto
V
,
Pace
A
, et al.
A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors
.
J Clin Endocrinol Metab
.
2008
;
93
(
5
):
1582
91
. .
74.
Frucht
H
,
Howard
JM
,
Slaff
JI
,
Wank
SA
,
McCarthy
DM
,
Maton
PN
, et al.
Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study
.
Ann Intern Med
.
1989
;
111
(
9
):
713
22
. .
75.
Roy
PK
,
Venzon
DJ
,
Shojamanesh
H
,
Abou-Saif
A
,
Peghini
P
,
Doppman
JL
, et al.
Zollinger-Ellison syndrome. Clinical presentation in 261 patients
.
Medicine
.
2000
;
79
(
6
):
379
411
. .
76.
Cryer
PE
,
Axelrod
L
,
Grossman
AB
,
Heller
SR
,
Montori
VM
,
Seaquist
ER
, et al.
Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline
.
J Clin Endocrinol Metab
.
2009
;
94
(
3
):
709
28
. .
77.
Metz
DC
,
Jensen
RT
.
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors
.
Gastroenterology
.
2008
;
135
(
5
):
1469
92
. .
78.
Kim
GY
,
Kim
S
,
Ong
RKS
,
Shawa
H
.
Simultaneous glucagon and vasoactive intestinal peptide producing pancreatic neuroendocrine tumors in a patient with multiple endocrine neoplasia type 1: a case report and literature review
.
Pancreas
.
2018
;
47
:
e1
2
.
79.
Thakker
RV
,
Newey
PJ
,
Walls
GV
,
Bilezikian
J
,
Dralle
H
,
Ebeling
PR
, et al.
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)
.
J Clin Endocrinol Metab
.
2012
;
97
(
9
):
2990
3011
. .
80.
Casey
RT
,
Saunders
D
,
Challis
BG
,
Pitfield
D
,
Cheow
H
,
Shaw
A
, et al.
Radiological surveillance in multiple endocrine neoplasia type 1: a double-edged sword?
Endocr Connect
.
2017
;
6
(
3
):
151
8
. .
81.
Albers
MB
,
Librizzi
D
,
Lopez
CL
,
Manoharan
J
,
Apitzsch
JC
,
Slater
EP
, et al.
Limited value of Ga-68-DOTATOC-PET-CT in routine screening of patients with multiple endocrine neoplasia type 1
.
World J Surg
.
2017
;
41
(
6
):
1521
7
. .
82.
Rockall
AG
,
Reznek
RH
.
Imaging of neuroendocrine tumours (CT/MR/US)
.
Best Pract Res Clin Endocrinol Metab
.
2007
;
21
(
1
):
43
68
. .
83.
Noone
TC
,
Hosey
J
,
Firat
Z
,
Semelka
RC
.
Imaging and localization of islet-cell tumours of the pancreas on CT and MRI
.
Best Pract Res Clin Endocrinol Metab
.
2005
;
19
(
2
):
195
211
. .
84.
Reubi
JC
.
Peptide receptors as molecular targets for cancer diagnosis and therapy
.
Endocr Rev
.
2003
;
24
(
4
):
389
427
. .
85.
Haug
A
,
Auernhammer
CJ
,
Wängler
B
,
Tiling
R
,
Schmidt
G
,
Göke
B
, et al.
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours
.
Eur J Nucl Med Mol Imaging
.
2009
;
36
(
5
):
765
70
. .
86.
Koukouraki
S
,
Strauss
LG
,
Georgoulias
V
,
Eisenhut
M
,
Haberkorn
U
,
Dimitrakopoulou-Strauss
A
.
Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
.
Eur J Nucl Med Mol Imaging
.
2006
;
33
(
10
):
1115
22
. .
87.
Kayani
I
,
Bomanji
JB
,
Groves
A
,
Conway
G
,
Gacinovic
S
,
Win
T
, et al.
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG
.
Cancer
.
2008
;
112
(
11
):
2447
55
. .
88.
Falconi
M
,
Bartsch
DK
,
Eriksson
B
,
Klöppel
G
,
Lopes
JM
,
O’Connor
JM
, et al.
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors
.
Neuroendocrinology
.
2012
;
95
(
2
):
120
34
. .
89.
Hofman
MS
,
Kong
G
,
Neels
OC
,
Eu
P
,
Hong
E
,
Hicks
RJ
.
High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
.
J Med Imaging Radiat Oncol
.
2012
;
56
(
1
):
40
7
. .
90.
Frilling
A
,
Sotiropoulos
GC
,
Radtke
A
,
Malago
M
,
Bockisch
A
,
Kuehl
H
, et al.
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors
.
Ann Surg
.
2010
;
252
(
5
):
850
6
. .
91.
Ruf
J
,
Heuck
F
,
Schiefer
J
,
Denecke
T
,
Elgeti
F
,
Pascher
A
, et al.
Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors
.
Neuroendocrinology
.
2010
;
91
(
1
):
101
9
. .
92.
van Treijen
MJC
,
van Beek
D-J
,
van Leeuwaarde
RS
,
Vriens
MR
,
Valk
GD
.
Diagnosing nonfunctional pancreatic NETs in MEN1: the evidence base
.
J Endocr Soc
.
2018
;
2
(
9
):
1067
88
. .
93.
Antwi
K
,
Nicolas
G
,
Fani
M
,
Heye
T
,
Pattou
F
,
Grossman
A
, et al.
68Ga-exendin-4 PET/CT detects insulinomas in patients with endogenous hyperinsulinemic hypoglycemia in MEN-1
.
J Clin Endocrinol Metab
.
2019 Dec 1
;
104
(
12
):
5843
52
. .
94.
Doppman
JL
,
Miller
DL
,
Chang
R
,
Shawker
TH
,
Gorden
P
,
Norton
JA
.
Insulinomas: localization with selective intraarterial injection of calcium
.
Radiology
.
1991
;
178
(
1
):
237
41
. .
95.
Imamura
M
,
Komoto
I
,
Ota
S
,
Hiratsuka
T
,
Kosugi
S
,
Doi
R
, et al.
Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients
.
World J Gastroenterol
.
2011
;
17
(
10
):
1343
53
. .
96.
Polenta
V
,
Slater
EP
,
Kann
PH
,
Albers
MB
,
Manoharan
J
,
Ramaswamy
A
,
Preoperative imaging overestimates the tumor size in pancreatic neuroendocrine neoplasms associated with multiple endocrine neoplasia type 1
.
World J Surg
.
2018
;
42
(
5
):
1440
7
.
97.
et al
P
,
Hennings
J
,
Akerstrom
G
,
Akerström
B
.
Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1
.
Br J Surg
.
2005
;
92
(
12
):
1508
12
. .
98.
Langer
P
,
Kann
PH
,
Fendrich
V
,
Richter
G
,
Diehl
S
,
Rothmund
M
, et al.
Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1
.
World J Surg
.
2004
;
28
(
12
):
1317
22
. .
99.
Lewis
MA
,
Thompson
GB
,
Young
WF
 Jr
.
Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1
.
World J Surg
.
2012
;
36
(
6
):
1375
81
. .
100.
van Asselt
SJ
,
Brouwers
AH
,
van Dullemen
HM
,
van der Jagt
EJ
,
Bongaerts
AH
,
Kema
IP
, et al.
EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1
.
Gastrointest Endosc
.
2015
;
81
(
1
):
159
e2
. .
101.
Triponez
F
,
Dosseh
D
,
Goudet
P
,
Cougard
P
,
Bauters
C
,
Murat
A
, et al.
Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas
.
Ann Surg
.
2006
;
243
(
2
):
265
72
. .
102.
Kouvaraki
MA
,
Shapiro
SE
,
Cote
GJ
,
Lee
JE
,
Yao
JC
,
Waguespack
SG
, et al.
Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1
.
World J Surg
.
2006
;
30
(
5
):
643
53
. .
103.
Akerstrom
G
,
Stalberg
P
,
Hellman
P
.
Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1
.
Clinics
.
2012
;
67
(
Suppl 1
):
173
8
.
104.
Bartsch
DK
,
Fendrich
V
,
Langer
P
,
Celik
I
,
Kann
PH
,
Rothmund
M
.
Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1
.
Ann Surg
.
2005
;
242
(
6
):
757
6
;
discussion 764–6
. .
105.
Hanazaki
K
,
Sakurai
A
,
Munekage
M
,
Ichikawa
K
,
Namikawa
T
,
Okabayashi
T
, et al.
Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1
.
Surg Today
.
2013
;
43
(
3
):
229
36
. .
106.
Sadowski
SM
,
Triponez
F
.
Management of pancreatic neuroendocrine tumors in patients with MEN 1
.
Gland Surg
.
2015
;
4
(
1
):
63
8
. .
107.
Sadowski
SM
,
Cadiot
G
,
Dansin
E
,
Goudet
P
,
Triponez
F
.
The future: surgical advances in MEN1 therapeutic approaches and management strategies
.
Endocr Relat Cancer
.
2017
;
24
(
10
):
T243
260
. .
108.
Triponez
F
,
Sadowski
SM
,
Pattou
F
,
Cardot-Bauters
C
,
Mirallie
E
,
Le Bras
M
, et al.
Long-term follow-up of MEN1 patients who do not have initial surgery for small </=2 cm nonfunctioning pancreatic neuroendocrine tumors, an AFCE and GTE study: association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines
.
Ann Surg
.
2018 Jul
;
268
(
1
):
158
64
.
109.
Triponez
F
,
Sadowski
SM
,
Pattou
F
,
Cardot-Bauters
C
,
Mirallie
E
,
Le Bras
M
, et al.
Long-term follow-up of MEN1 patients who do not have initial surgery for small </=2 cm nonfunctioning pancreatic neuroendocrine tumors, an AFCE and GTE study: association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines
.
Ann Surg
.
2018
;
268
:
158
64
.
110.
Vinault
S
,
Mariet
AS
,
Le Bras
M
,
Mirallie
E
,
Cardot-Bauters
C
,
Pattou
F
, et al.
Metastatic potential and survival of duodenal and pancreatic tumors in multiple endocrine neoplasia type 1: a GTE and AFCE Cohort Study (Groupe d’etude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne)
.
Ann Surg
.
2018
.
Epub ahead of print
.
111.
Norton
JA
,
Fraker
DL
,
Alexander
HR
,
Gibril
F
,
Liewehr
DJ
,
Venzon
DJ
, et al.
Surgery increases survival in patients with gastrinoma
.
Ann Surg
.
2006
;
244
(
3
):
410
9
. .
112.
Norton
JA
.
Surgical treatment and prognosis of gastrinoma
.
Best Pract Res Clin Gastroenterol
.
2005
;
19
(
5
):
799
805
. .
113.
Bartsch
DK
,
Langer
P
,
Wild
A
,
Schilling
T
,
Celik
I
,
Rothmund
M
, et al.
Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?
Surgery
.
2000
;
128
(
6
):
958
66
. .
114.
Lopez
CL
,
Falconi
M
,
Waldmann
J
,
Boninsegna
L
,
Fendrich
V
,
Goretzki
PK
, et al.
Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1
.
Ann Surg
.
2013
;
257
(
2
):
308
14
. .
115.
Selberherr
A
,
Koperek
O
,
Riss
P
,
Scheuba
C
,
Niederle
MB
,
Kaderli
R
,
Intertumor heterogeneity in 60 pancreatic neuroendocrine tumors associated with multiple endocrine neoplasia type 1
.
Orphanet J Rare Dis
.
2019
;
14
(
1
):
54
.
116.
de Wilde
RF
,
Heaphy
CM
,
Maitra
A
,
Meeker
AK
,
Edil
BH
,
Wolfgang
CL
, et al.
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
.
Mod Pathol
.
2012
;
25
:
1033
9
.
117.
Sadowski
SM
,
Pieterman
CRC
,
Perrier
ND
,
Triponez
F
,
Valk
GD
.
Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature
.
Endocr Relat Cancer
.
2020
;
27
(
6
):
R145
61
. .
118.
Klimstra
DSKG
,
La Rosa
S
,
Rindi
G
.
Classification of neuroendocrine neoplasms of the digestive system
.
Lyon, France
:
International Agency for Research on Cancer
;
2019
.
119.
Thevenon
J
,
Bourredjem
A
,
Faivre
L
,
Cardot-Bauters
C
,
Calender
A
,
Murat
A
, et al.
Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d’etude des Tumeurs Endocrines (GTE) cohort study
.
Hum Mol Genet
.
2013
;
22
(
10
):
1940
8
. .
120.
Bartsch
DK
,
Slater
EP
,
Albers
M
,
Knoop
R
,
Chaloupka
B
,
Lopez
CL
, et al.
Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain
.
J Clin Endocrinol Metab
.
2014
;
99
(
11
):
E2387
91
. .
121.
Christakis
I
,
Qiu
W
,
Hyde
SM
,
Cote
GJ
,
Grubbs
EG
,
Perrier
ND
, et al.
Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: a 23-year experience at a single institution
.
Surgery
.
2018
;
163
:
212
7
.
122.
Hasani-Ranjbar
S
,
Amoli
MM
,
Ebrahim-Habibi
A
,
Gozashti
MH
,
Khalili
N
,
Sayyahpour
FA
, et al.
A new frameshift MEN1 gene mutation associated with familial malignant insulinomas
.
Fam Cancer
.
2011
;
10
(
2
):
343
8
. .
123.
Raef
H
,
Zou
M
,
Baitei
EY
,
Al-Rijjal
RA
,
Kaya
N
,
Al-Hamed
M
, et al.
A novel deletion of the MEN1 gene in a large family of multiple endocrine neoplasia type 1 (MEN1) with aggressive phenotype
.
Clin Endocrinol
.
2011
;
75
(
6
):
791
800
. .
124.
Anlauf
M
,
Garbrecht
N
,
Henopp
T
,
Schmitt
A
,
Schlenger
R
,
Raffel
A
, et al.
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features
.
World J Gastroenterol
.
2006
;
12
(
34
):
5440
6
. .
125.
Norton
JA
,
Alexander
HR
,
Fraker
DL
,
Venzon
DJ
,
Gibril
F
,
Jensen
RT
.
Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome
.
Ann Surg
.
2001
;
234
(
4
):
495
6
;
discussion 505–496
. .
126.
Pipeleers-Marichal
M
,
Somers
G
,
Willems
G
,
Foulis
A
,
Imrie
C
,
Bishop
AE
, et al.
Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome
.
N Engl J Med
.
1990
;
322
(
11
):
723
7
. .
127.
Anlauf
M
,
Enosawa
T
,
Henopp
T
,
Schmitt
A
,
Gimm
O
,
Brauckhoff
M
, et al.
Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor
.
Am J Surg Pathol
.
2008
;
32
(
7
):
1101
5
. .
128.
Thompson
NW
.
Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both
.
J Intern Med
.
1998
;
243
(
6
):
495
500
. .
129.
Cadiot
G
,
Vuagnat
A
,
Doukhan
I
,
Murat
A
,
Bonnaud
G
,
Delemer
B
, et al.
Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d’Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d’Etude du Syndrome de Zollinger-Ellison (GRESZE)
.
Gastroenterology
.
1999
;
116
:
286
93
.
130.
Weber
HC
,
Venzon
DJ
,
Lin
JT
,
Fishbein
VA
,
Orbuch
M
,
Strader
DB
, et al.
Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study
.
Gastroenterology
.
1995
;
108
(
6
):
1637
49
. .
131.
Yu
F
,
Venzon
DJ
,
Serrano
J
,
Goebel
SU
,
Doppman
JL
,
Gibril
F
, et al.
Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome
.
J Clin Oncol
.
1999
;
17
(
2
):
615
30
. .
132.
Norton
JA
,
Jensen
RT
.
Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome
.
Ann Surg
.
2004
;
240
(
5
):
757
73
. .
133.
Gibril
F
,
Venzon
DJ
,
Ojeaburu
JV
,
Bashir
S
,
Jensen
RT
.
Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form
.
J Clin Endocrinol Metab
.
2001
;
86
(
11
):
5282
93
. .
134.
Norton
JA
,
Cornelius
MJ
,
Doppman
JL
,
Maton
PN
,
Gardner
JD
,
Jensen
RT
.
Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study
.
Surgery
.
1987
;
102
(
6
):
958
66
.
135.
Lee
MJ
,
Jung
CH
,
Jang
JE
,
Hwang
JY
,
Park
DH
,
Park
TS
, et al.
Successful endoscopic ultrasound-guided ethanol ablation of multiple insulinomas accompanied with multiple endocrine neoplasia type 1
.
Intern Med J
.
2013
;
43
(
8
):
948
50
. .
136.
Tonelli
F
.
How to follow up and when to operate asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1?
J Clin Gastroenterol
.
2014
;
48
(
5
):
387
9
. .
137.
Tonelli
F
,
Fratini
G
,
Falchetti
A
,
Nesi
G
,
Brandi
ML
.
Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience
.
J Intern Med
.
2005
;
257
(
1
):
38
49
. .
138.
Bartsch
DK
,
Albers
M
,
Knoop
R
,
Kann
PH
,
Fendrich
V
,
Waldmann
J
.
Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1
.
Neuroendocrinology
.
2013
;
98
(
4
):
290
8
. .
139.
Harper
S
,
Harrison
B
.
First surgery for pancreatic neuroendocrine tumours in a patient with MEN1: enucleation versus disease-modifying surgery
.
Clin Endocrinol
.
2015
;
83
(
5
):
618
21
. .
140.
Norton
JA
,
Krampitz
G
,
Zemek
A
,
Longacre
T
,
Jensen
RT
.
Better survival but changing causes of death in patients with multiple endocrine neoplasia type 1
.
Ann Surg
.
2015
;
261
(
6
):
e147
. .
141.
Hausman
MS
 Jr
,
Thompson
NW
,
Gauger
PG
,
Doherty
GM
.
The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease
.
Surgery
.
2004
;
136
(
6
):
1205
11
. .
142.
Gauger
PG
,
Doherty
GM
,
Broome
JT
,
Miller
BS
,
Thompson
NW
.
Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms
.
Surgery
.
2009
;
146
(
4
):
801
8
;
discussion 807–8
. .
143.
Ratnayake
CBB
,
Loveday
BP
,
Windsor
JA
,
Lawrence
B
,
Pandanaboyana
S
.
Patient characteristics and clinical outcomes following initial surgical intervention for MEN1 associated pancreatic neuroendocrine tumours: a systematic review and exploratory meta-analysis of the literature
.
Pancreatology
.
2019
;
19
(
3
):
462
71
. .
144.
Fernandez-Cruz
L
,
Blanco
L
,
Cosa
R
,
Rendon
H
.
Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?
World J Surg
.
2008
;
32
:
904
17
.
145.
Fernandez-Cruz
L
,
Molina
V
,
Vallejos
R
,
Jimenez Chavarria
E
,
Lopez-Boado
MA
,
Ferrer
J
.
Outcome after laparoscopic enucleation for non-functional neuroendocrine pancreatic tumours
.
HPB
.
2012
;
14
:
171
6
.
146.
Haugvik
SP
,
Marangos
IP
,
Røsok
BI
,
Pomianowska
E
,
Gladhaug
IP
,
Mathisen
O
, et al.
Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors
.
World J Surg
.
2013
;
37
(
3
):
582
90
. .
147.
Lopez
CL
,
Albers
MB
,
Bollmann
C
,
Manoharan
J
,
Waldmann
J
,
Fendrich
V
, et al.
Minimally invasive versus open pancreatic surgery in patients with multiple endocrine neoplasia type 1
.
World J Surg
.
2016
;
40
(
7
):
1729
36
. .
148.
Blanc
P
,
Porcheron
J
,
Pages
A
,
Breton
C
,
Mosnier
JF
,
Balique
JG
.
[Laparoscopic excision of a duodenal neuroendocrine tumor]
.
Ann Chir
.
2000
;
125
(
2
):
176
8
. .
149.
Kim
SC
,
Song
KB
,
Jung
YS
,
Kim
YH
,
Park
DH
,
Lee
SS
, et al.
Short-term clinical outcomes for 100 consecutive cases of laparoscopic pylorus-preserving pancreatoduodenectomy: improvement with surgical experience
.
Surg Endosc
.
2013
;
27
(
1
):
95
103
. .
150.
Zureikat
AH
,
Nguyen
KT
,
Bartlett
DL
,
Zeh
HJ
,
Moser
AJ
.
Robotic-assisted major pancreatic resection and reconstruction
.
Arch Surg
.
2011
;
146
(
3
):
256
61
. .
151.
Pavel
M
,
Baudin
E
,
Couvelard
A
,
Krenning
E
,
Öberg
K
,
Steinmüller
T
, et al.
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary
.
Neuroendocrinology
.
2012
;
95
(
2
):
157
76
. .
152.
Dy
BM
,
Que
FG
,
Thompson
GB
,
Young
WF
,
Rowse
P
,
Strajina
V
, et al.
Metastasectomy of neuroendocrine tumors in patients with multiple endocrine neoplasia type 1
.
Am J Surg
.
2014
;
208
(
6
):
1047
3
;
discussion 1052–3
.
153.
Chiloiro
S
,
Lanza
F
,
Bianchi
A
,
Schinzari
G
,
Brizi
MG
,
Giampietro
A
.
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study
.
Endocrine
.
2018
;
60
(
2
):
362
7
.
154.
Bertani
E
,
Fazio
N
,
Botteri
E
,
Chiappa
A
,
Falconi
M
,
Grana
C
, et al.
Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach
.
Surgery
.
2014
;
155
(
4
):
607
14
. .
155.
Capurso
G
,
Bettini
R
,
Rinzivillo
M
,
Boninsegna
L
,
Delle Fave
G
,
Falconi
M
.
Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review
.
Neuroendocrinology
.
2011
;
93
(
4
):
223
9
. .
156.
Frilling
A
,
Modlin
IM
,
Kidd
M
,
Russell
C
,
Breitenstein
S
,
Salem
R
, et al.
Recommendations for management of patients with neuroendocrine liver metastases
.
Lancet Oncol
.
2014
;
15
(
1
):
e8
21
. .
157.
Partelli
S
,
Cirocchi
R
,
Rancoita
PMV
,
Muffatti
F
,
Andreasi
V
,
Crippa
S
,
Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases
.
HPB
.
2018
;
20
(
3
):
197
203
.
158.
Scigliano
S
,
Lebtahi
R
,
Maire
F
,
Stievenart
JL
,
Kianmanesh
R
,
Sauvanet
A
, et al.
Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience
.
Endocr Relat Cancer
.
2009
;
16
(
3
):
977
90
. .
159.
Chamberlain
RS
,
Canes
D
,
Brown
KT
,
Saltz
L
,
Jarnagin
W
,
Fong
Y
, et al.
Hepatic neuroendocrine metastases: does intervention alter outcomes?
J Am Coll Surg
.
2000
;
190
(
4
):
432
45
. .
160.
Hori
T
,
Takaori
K
,
Uemoto
S
.
Pancreatic neuroendocrine tumor accompanied with multiple liver metastases
.
World J Hepatol
.
2014
;
6
(
8
):
596
600
. .
161.
Modlin
IM
,
Oberg
K
,
Chung
DC
,
Jensen
RT
,
de Herder
WW
,
Thakker
RV
, et al.
Gastroenteropancreatic neuroendocrine tumours
.
Lancet Oncol
.
2008
;
9
(
1
):
61
72
. .
162.
Pieterman
CRC
,
Sadowski
SM
,
Maxwell
JE
,
Katz
MHG
,
Lines
KE
,
Heaphy
CM
, et al.
MEN1-related PanNETs: identifying unmet clinical needs and future directives
.
Endocr Relat Cancer
.
2020
;
27
(
8
).
163.
de Laat
JM
,
van der Luijt
RB
,
Pieterman
CR
,
Oostveen
MP
,
Hermus
AR
,
Dekkers
OM
, et al.
MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients
.
BMC Med
.
2016
;
14
(
1
):
182
. .
164.
Sakurai
A
,
Suzuki
S
,
Kosugi
S
,
Okamoto
T
,
Uchino
S
,
Miya
A
, et al.
Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database
.
Clin Endocrinol
.
2012
;
76
(
4
):
533
9
. .
165.
Conemans
EB
,
Brosens
LAA
,
Raicu-Ionita
GM
,
Pieterman
CRC
,
de Herder
WW
,
Dekkers
OM
, et al.
Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in multiple endocrine neoplasia type 1: results from the DutchMEN1 study group
.
Pancreatology
.
2017
;
17
(
5
):
766
72
. .
166.
Ito
T
,
Igarashi
H
,
Uehara
H
,
Jensen
RT
.
Pharmacotherapy of Zollinger-Ellison syndrome
.
Expert Opin Pharmacother
.
2013
;
14
(
3
):
307
21
. .
167.
Jensen
RT
,
Norton
JA
.
Treatment of pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: some clarity but continued controversy
.
Pancreas
.
2017
;
46
(
5
):
589
94
. .
168.
Gibril
F
,
Schumann
M
,
Pace
A
,
Jensen
RT
.
Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature
.
Medicine
.
2004
;
83
(
1
):
43
83
. .
169.
Roy
PK
,
Venzon
DJ
,
Feigenbaum
KM
,
Koviack
PD
,
Bashir
S
,
Ojeaburu
JV
, et al.
Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis–a prospective NIH study of 235 patients and a review of 984 cases in the literature
.
Medicine
.
2001
;
80
:
189
222
.
170.
Jensen
R
,
Gardner
JD
.
Gastrinoma
.
New York
:
Raven Press Publishing Co.
;
1993
.
171.
Ellison
EH
,
Wilson
SD
.
The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases
.
Ann Surg
.
1964
;
160
:
512
30
.
172.
Jensen
RT
,
Gardner
JD
,
Raufman
JP
,
Pandol
SJ
,
Doppman
JL
,
Collen
MJ
.
Zollinger-Ellison syndrome: current concepts and management
.
Ann Intern Med
.
1983
;
98
(
1
):
59
75
. .
173.
O’Riordain
DS
,
O’Brien
T
,
van Heerden
JA
,
Service
FJ
,
Grant
CS
.
Surgical management of insulinoma associated with multiple endocrine neoplasia type I
.
World J Surg
.
1994
;
18
(
4
):
488
4
;
discussion 493-484
.
174.
Sheppard
BC
,
Norton
JA
,
Doppman
JL
,
Maton
PN
,
Gardner
JD
,
Jensen
RT
.
Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study
.
Surgery
.
1989
;
106
(
6
):
1108
8
;
discussion 1117–8
.
175.
Tonelli
F
,
Giudici
F
,
Nesi
G
,
Batignani
G
,
Brandi
ML
.
Operation for insulinomas in multiple endocrine neoplasia type 1: when pancreatoduodenectomy is appropriate
.
Surgery
.
2017
;
161
(
3
):
727
34
. .
176.
Metz
DC
,
Sostek
MB
,
Ruszniewski
P
,
Forsmark
CE
,
Monyak
J
,
Pisegna
JR
.
Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion
.
Am J Gastroenterol
.
2007
;
102
(
12
):
2648
54
. .
177.
Morocutti
A
,
Merrouche
M
,
Bjaaland
T
,
Humphries
T
,
Mignon
M
.
An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion
.
Aliment Pharmacol Ther
.
2006
;
24
(
10
):
1439
44
. .
178.
Yang
YX
,
Metz
DC
.
Safety of proton pump inhibitor exposure
.
Gastroenterology
.
2010
;
139
(
4
):
1115
27
. .
179.
Modlin
IM
,
Pavel
M
,
Kidd
M
,
Gustafsson
BI
.
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
.
Aliment Pharmacol Ther
.
2010
;
31
(
2
):
169
88
. .
180.
Ito
T
,
Lee
L
,
Jensen
RT
.
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies
.
Expert Opin Pharmacother
.
2016
;
17
(
16
):
2191
205
. .
181.
Goode
PN
,
Farndon
JR
,
Anderson
J
,
Johnston
ID
,
Morte
JA
.
Diazoxide in the management of patients with insulinoma
.
World J Surg
.
1986
;
10
(
4
):
586
92
. .
182.
Del Prete
M
,
Marotta
V
,
Ramundo
V
,
Marciello
F
,
Di Sarno
A
,
Esposito
R
,
Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1
.
Minerva Endocrinol
.
2013
;
38
(
4
):
389
94
.
183.
et al
F
,
Cianferotti
L
,
Gronchi
G
,
Cioppi
F
,
Masi
L
,
Faggiano
A
, et al.
Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1)
.
Endocrine
.
2016
;
52
(
3
):
495
506
. .
184.
Partelli
S
,
Bartsch
DK
,
Capdevila
J
,
Chen
J
,
Knigge
U
,
Niederle
B
, et al.
Antibes consensus conference p: ENETS Consensus Guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours
.
Neuroendocrinology
.
2017
;
105
:
255
65
.
185.
Cioppi
F
,
Cianferotti
L
,
Masi
L
,
Giusti
F
,
Brandi
ML
.
The LARO-MEN1 study: a longitudinal clinical experience with octreotide long-acting release in patients with multiple endocrine neoplasia type 1 syndrome
.
Clin Cases Miner Bone Metab
.
2017
;
14
(
2
):
123
30
. .
186.
Marciello
F
,
Di Somma
C
,
Del Prete
M
,
Marotta
V
,
Ramundo
V
,
Carratù
A
, et al.
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas
.
Endocrine
.
2014
;
46
(
3
):
678
81
. .
187.
Ramundo
V
,
Del Prete
M
,
Marotta
V
,
Marciello
F
,
Camera
L
,
Napolitano
V
;
Multidisciplinary Group for Neuroendocrine Tumors of N
, et al.
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours
.
Clin Endocrinol
.
2014
;
80
(
6
):
850
5
. .
188.
Faggiano
A
,
Modica
R
,
Lo Calzo
F
,
Camera
L
,
Napolitano
V
,
Altieri
B
, et al.
Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors <2 cm
.
J Clin Endocrinol Metab
.
2020 Jan 1
;
105
(
1
):
dgz007
. .
189.
Frost
M
,
Lines
KE
,
Thakker
RV
.
Current and emerging therapies for PNETs in patients with or without MEN1
.
Nat Rev Endocrinol
.
2018
;
14
(
4
):
216
27
. .
190.
de Herder
WW
,
Niederle
B
,
Scoazec
JY
,
Pauwels
S
,
Kloppel
G
,
Falconi
M
;
European Neuroendocrine Tumor S
, et al.
Well-differentiated pancreatic tumor/carcinoma: insulinoma
.
Neuroendocrinology
.
2006
;
84
(
3
):
183
8
. .
191.
Oberg
K
,
Kvols
L
,
Caplin
M
,
Delle Fave
G
,
de Herder
W
,
Rindi
G
, et al.
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
.
Ann Oncol
.
2004
;
15
(
6
):
966
73
. .
192.
Kulke
MH
,
Bergsland
EK
,
Yao
JC
.
Glycemic control in patients with insulinoma treated with everolimus
.
N Engl J Med
.
2009
;
360
(
2
):
195
7
. .
193.
Novruzov
F
,
Mehmetbeyli
L
,
Aliyev
JA
,
Abbasov
B
,
Mehdi
E
.
Metastatic insulinoma controlled by targeted radionuclide therapy with 177Lu-DOTATATE in a patient with solitary kidney and MEN-1 syndrome
.
Clin Nucl Med
.
2019
;
44
(
6
):
e415
7
. .
194.
Naik
C
,
Basu
S
.
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and Cushing’s syndrome
.
World J Nucl Med
.
2017
;
16
:
126
32
.
195.
Grozinsky-Glasberg
S
,
Lines
KE
,
Avniel-Polak
S
,
Bountra
C
,
Thakker
RV
.
Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs)
.
Endocr Relat Cancer
.
2020 Sep
;
27
(
9
):
R345
5
.
196.
Garcia-Carbonero
R
,
Sorbye
H
,
Baudin
E
,
Raymond
E
,
Wiedenmann
B
,
Niederle
B
;
Vienna Consensus Conference p
, et al.
ENETS Consensus Guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas
.
Neuroendocrinology
.
2016
;
103
(
2
):
186
94
. .
197.
Daglar
HK
,
Kirbas
A
,
Biberoglu
E
,
Laleli
B
,
Danisman
N
.
Management of a multiple endocrine neoplasia type 1 during pregnancy: a case report and review of the literature
.
J Exp Ther Oncol
.
2016
;
11
(
3
):
217
20
.
198.
Mistry
M
,
Gupta
M
,
Kaler
M
.
Pregnancy in multiple endocrine neoplasia type 1 equals multiple complications
.
Obstet Med
.
2014
;
7
(
3
):
123
5
. .
199.
Stewart
CA
,
Termanini
B
,
Sutliff
VE
,
Corleto
VD
,
Weber
HC
,
Gibril
F
, et al.
Management of the Zollinger-Ellison syndrome in pregnancy
.
Am J Obstet Gynecol
.
1997
;
176
(
1 Pt 1
):
224
33
. .
200.
Gulati
Anthony P.
,
Krantz
Benjamin
,
Moss
Rebecca A.
,
Moyal
Wendy N.
,
Tsushima
Dawn A.
,
Mowatt
Kelley B.
, et al.
Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature
.
Oncology
.
2013
;
84
(
3
):
127
34
.
201.
Zandee
Wouter T
,
Brabander
Tessa
,
Blažević
Anela
,
Kam
Boen L R
,
Teunissen
Jaap J M
,
Feelders
Richard A
, et al.
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors
.
J Clin Endocrinol Metab
.
2019
;
104
(
4
):
1336
44
. .
[PubMed]
.
202.
Gezer
Emre
,
Çetinarslan
Berrin
,
Cantürk
Zeynep
,
Tarkun
İilhan
,
Sözen
Mehmet
,
Selek
Alev
.
Metastatic MEN1 Syndrome Treated with Lutetium-177 - A Case Report
.
Eur Endocrinol
.
2019
;
15
(
2
):
92
4
. .
[PubMed]
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.